NuCana plc - American Depositary Share (NCNA): Price and Financial Metrics


NuCana plc - American Depositary Share (NCNA): $0.60

-0.02 (-3.39%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

Add NCNA to Watchlist
Sign Up

Industry: Biotech


Ranked

of

in industry

NCNA Stock Price Chart Interactive Chart >

Price chart for NCNA

NCNA Price/Volume Stats

Current price $0.60 52-week high $3.32
Prev. close $0.62 52-week low $0.52
Day low $0.59 Volume 203,100
Day high $0.62 Avg. volume 394,189
50-day MA $0.82 Dividend yield N/A
200-day MA $2.04 Market Cap 31.26M

NuCana plc - American Depositary Share (NCNA) Company Bio


NuCana plc develops anti-cancer medicines for ovarian, biliary, pancreatic, colorectal, haematology, oncology, and breast cancers. NuCana produces oncology medicines using a proprietary technology platform for cancer patients. The company was incorporated in 1997 and is based in Edinburgh, the United Kingdom.


NCNA Latest News Stream


Event/Time News Detail
Loading, please wait...

NCNA Latest Social Stream


Loading social stream, please wait...

View Full NCNA Social Stream

Latest NCNA News From Around the Web

Below are the latest news stories about NuCana plc that investors may wish to consider to help them evaluate NCNA as an investment opportunity.

NuCana Announces Enrollment of Required Number of Patients to Conduct Second Interim Analysis in the Phase III Biliary Tract Cancer Study

Enrollment of 644 Evaluable Patients Expected to Enable Second Interim Analysis in the Second Half of 2022 First Interim Analysis of 418 Evaluable Patients Remains on Track for the First Half of 2022 Data from Either Interim Analysis May Support an NDA Submission in the United States under the FDA’s Accelerated Approval Program EDINBURGH, United Kingdom, Feb. 22, 2022 (GLOBE NEWSWIRE) -- NuCana plc (NASDAQ: NCNA) announced it has completed enrollment of the number of patients in the ongoing Phas

Yahoo | February 22, 2022

What You Need To Know About NuCana plc's (NASDAQ:NCNA) Investor Composition

If you want to know who really controls NuCana plc ( NASDAQ:NCNA ), then you'll have to look at the makeup of its share...

Yahoo | February 1, 2022

Is NuCana PLC Sponsored ADR (NCNA) Outperforming Other Medical Stocks This Year?

Here is how NuCana PLC Sponsored ADR (NCNA) and OptiNose (OPTN) have performed compared to their sector so far this year.

Yahoo | January 24, 2022

Opaleye Management Inc. Buys Semler Scientific Inc, Keros Therapeutics Inc, Crinetics ...

Cambridge, MA, based Investment company Opaleye Management Inc. (Current Portfolio) buys Semler Scientific Inc, Keros Therapeutics Inc, Crinetics Pharmaceuticals Inc, Amicus Therapeutics Inc, Merus NV, sells ESSA Pharma Inc, Seres Therapeutics Inc, CM Life Sciences Inc, Lumos Pharma Inc, Kezar Life Sciences Inc during the 3-months ended 2021Q3, according to the most recent filings of the investment company, Opaleye Management Inc..

Yahoo | December 28, 2021

-$0.25 EPS Expected for NuCana plc (NASDAQ:NCNA) This Quarter

Analysts expect that NuCana plc (NASDAQ:NCNA) will post ($0.25) earnings per share (EPS) for the current fiscal quarter, according to Zacks. Zero analysts have provided estimates for NuCanas earnings, with estimates ranging from ($0.29) to ($0.17). NuCana reported earnings per share of ($0.32) during the same quarter last year, which suggests a positive year over []

Dakota Financial News | December 21, 2021

Read More 'NCNA' Stories Here

NCNA Price Returns

1-mo -18.92%
3-mo -78.26%
6-mo -78.49%
1-year -80.39%
3-year -95.65%
5-year N/A
YTD -74.79%
2021 -46.99%
2020 -26.39%
2019 -57.93%
2018 43.42%
2017 N/A

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!


Page generated in 0.6012 seconds.